CA-TYLIN
16.3.2022 22:25:11 CET | Business Wire | Press release
T.Y. Lin International, a globally recognized full-service infrastructure consulting firm, has unveiled a new brand strategy to unify its global operations. The unified brand will connect clients more effectively with TYLin’s multi-discipline global engineering resources to solve infrastructure challenges with innovative and technically advanced solutions at the regional and local levels.
Effective immediately, the company formerly known as T.Y. Lin International will go to market as TYLin . A redesigned logo, also part of the new brand strategy, represents the concept of “Connections” which is at the heart of the TYLin brand story. As a global engineering firm, TYLin connects clients with innovative thinking and global resources to solve their most important infrastructure challenges and enhance how people, places, and communities connect.
The story behind the development of the new TYLin brand and logo can be reviewed on the company’s new website www.TYLin.com .
Historically, TYLin has been recognized for its expertise in designing iconic bridges. Over the years, the company has established itself as a global leader providing engineering services and thought leadership to all segments of the built environment, including aviation, buildings, rail and transit, roads and highways, and water, in addition to bridges. TYLin’s strategic brand positioning highlights the company’s extensive knowledge and experience across all these sectors.
“The refreshed TYLin brand builds on the legacy of innovation created by our founder, Professor Tung-Yen (T.Y.) Lin, and the long-standing relationships we have with our clients around the world,” said Matthew Cummings, PE, TYLin President and Chief Executive Officer. “The rebranding signals our renewed commitment to connect our clients with the technical expertise, innovative thinking, and resources they need so that together we can continue to elevate the lives of people in the communities we serve. It will also foster unity within our firm, streamlining the processes for our employees to connect and collaborate with their global colleagues.”
The new TYLin brand is based on three key pillars: Approachable People who understand clients’ objectives and collaborate to provide seamless delivery of technological solutions through a lifecycle approach; Proven Capabilities and technical excellence; and access to Global Experience with innovative designs in advanced mobility infrastructure, smart buildings, and sustainable water solutions.
Since 1989, TYLin has been part of Dar Group , an international network of professional services firms comprising more than 17,000 staff in over 100 countries. TYLin, the lead brand within Dar’s Global Infrastructure (GI) Pillar, has 3,200 employees in 11 countries.
The strategy to unify the TYLin global brand is part of a phased, multi-year approach that will more closely align all TYLin offices and GI Pillar companies worldwide and facilitate access to global resources to support clients and provide enhanced career development opportunities for employees.
About TYLin:
Founded in 1954, TYLin is a globally recognized, full-service infrastructure consulting firm committed to providing innovative, cost-effective, constructible designs for the global infrastructure market. With 3,200 employees working in 65 offices throughout the Americas, Asia, and Europe, the firm provides support on projects of varying size and complexity. TYLin is a member of Dar Group, a global, privately-owned professional services group, and its industry-leading family of Global Infrastructure companies. For more information about the company, please visit www.tylin.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220316006051/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom